Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Prevention Habits of Medical Doctors

NCT07829601 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-06-27
Last updated
2026-09-24

Condition(s) studied

Preventive Practice

Investigational drug(s) / intervention(s)

PREVMED questionnaire

PREVMED questionnaire: Anonymous self-administered online questionnaire assessing physicians' preventive practices toward their patients, as well as sociodemographic, occupational, and lifestyle factors that may influence these practices.

Study summary

Preventive practices among physicians remain insufficiently studied, particularly in situations for which recommendations are limited or unavailable.

The PREVMED study aims to describe physicians' preventive practices and to investigate the sociodemographic, occupational, and lifestyle factors that may influence these practices.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Physician or medical resident volunteering to participate in the study. Exclusion Criteria: * Person not willing to participate in the study.

Primary outcome measure(s)

  • Assessment of patients' preventive health behaviors — Baseline
    Frequency of assessment of patients regarding physical activity, diet, tobacco consumption, alcohol consumption, cannabis consumption, and sun exposure. Each item is assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent assessment.
  • Oral preventive advice provided to patients — Baseline
    Frequency of oral advice provided to patients regarding physical activity, diet, tobacco consumption, alcohol consumption, cannabis consumption, and sun exposure. Each item is assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent provision of oral advice.
  • Written preventive advice or treatment prescribed to patients — Baseline
    Frequency of written advice or treatment prescribed to patients regarding physical activity, diet, tobacco consumption, alcohol consumption, cannabis consumption, and sun exposure. Each item is assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent prescription of written advice or treatment.
  • Referral to dedicated preventive consultations — Baseline
    Frequency of referral of patients to dedicated consultations for physical activity, diet, tobacco consumption, alcohol consumption, cannabis consumption, and sun exposure. Each item is assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent referral.
  • Verification of recommended screening and medical examinations — Baseline
    Frequency with which physicians ensure that patients undergo mammography for organized breast cancer screening, cervical screening, fecal occult blood testing for organized colorectal cancer screening, and regular blood tests. Each item is assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent verification.
  • Lung cancer screening practice — Baseline
    Frequency of proposing lung cancer screening to asymptomatic patients at risk, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent proposal of lung cancer screening.
  • Breast palpation practice — Baseline
    Frequency of proposing breast palpation to patients, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent proposal of breast palpation.
  • Cervical screening practice — Baseline
    Frequency of proposing cervical screening, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent proposal of cervical screening.
  • Prostate cancer screening practice — Baseline
    Frequency of proposing prostate cancer screening, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent proposal of prostate cancer screening.
  • Recommendation of skin self-examination — Baseline
    Frequency of advising patients to perform skin self-examination, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent recommendation of skin self-examination.
  • Visual skin examination — Baseline
    Frequency of performing visual skin examination, assessed using a visual analog scale ranging from 0 (never) to 100 (always), with higher scores indicating more frequent visual skin examination.
  • Frequency of screening blood tests — Baseline
    Frequency of prescription of screening blood tests, categorized as occasionally without a defined frequency, once a year, once every 2 years, every 3 to 5 years, more than 5 years apart, or more than 10 years apart.

Trial sites (1)

FacilityCityRegionStatus
Clermont-Ferrand University Hospital Clermont-Ferrand France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07829601 on ClinicalTrials.gov ↗ ← All trials in France